[Bio USA] SK Biopharmaceuticals doubles down on AI, open innovation

Korea Herald correspondent SAN DIEGO — SK Biopharmaceuticals has bet big on artificial intelligence and open innovation as the two core pillars that will drive the Korean drugmaker’s future growth.

“It took us almost 30 years to launch Xcopri as we did everything from development to commercialization and sales, unlike other firms,” said Lee Dong-hoon, CEO of SK Biopharmaceuticals, in a press conference at the BIO International Convention in San Diego on Monday.

The growing sales of Xcopri, which ...